Group-based or Individual Information About Disease and Treatment Plan
NCT ID: NCT01699672
Last Updated: 2017-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
98 participants
INTERVENTIONAL
2012-10-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary aims are to investigate if the addition of the educational program increases the likelihood of completing treatment as planned, reduces level of anxiety, reduces the frequency of serious side effects, increases patient reported health related quality of life, and increases the degree of patient satisfaction with respect to how they have received the information before, during and after treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cancer Patients' Knowledge About Fatigue
NCT00927433
Improving Communication With Patients With Breast Cancer
NCT00276822
Effects of Internet Support for Cancer Patients
NCT00971009
Improving Symptom Management for Cancer Patients and Their Caregivers Through Internet
NCT01867723
Improvement of Information to Cancer Patients' Caregivers
NCT02380469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators believe that standardizing and repeating the information as well as having more time for questions in an open environment for reflections will improve the amount of information patients can perceive. Furthermore, all patients will be given written information.
Better-informed patients may be more motivated and may contact health care personnel earlier than other patients when they develop side effects. This may reduce the risk of serious treatment-related complications and increase the chances of patients completing the planned treatment. But none have compared to what extent an organization like Vardesenteret improves the patients' knowledge and whether patients are more satisfied with these methods for informing them. Results from studies on the influence of patient anxiety and distress on patient's abilities to perceive information are conflicting.Two large groups of relatively homogenous cancer patients are patients with lower-stage breast cancer patients who are eligible for adjuvant chemotherapy and patients with localized prostate cancer eligible for curative radiotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group and Individual information
The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
Group information
The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
Individual information
Standard information about disease and treatment from doctor and nurse given at 2 occasions.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group information
The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prostate cancer patients that are candidates for curative radiotherapy
* Signed informed consent
* Patient expected to be able to complete the planned treatment and the study procedures
* 18years or older
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Olavs Hospital
OTHER
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stein Kaasa, MD, Prof.
Role: PRINCIPAL_INVESTIGATOR
St Olavs Hospital - Trondheim University Hospital and PRC, European Palliative Care Research Center
Ola Berger, MD
Role: STUDY_DIRECTOR
St Olavs Hospital - Trondheim University Hospital and PRC, European Palliative Care Research Center
Bjørn H Gønberg, MD, PhD
Role: STUDY_CHAIR
St Olavs Hospital - Trondheim University Hospital and PRC, European Palliative Care Research Center
Kari Sand, Cand Philol
Role: STUDY_CHAIR
PRC, European Palliative Care Research Center
Jo Å Lund, MD, PhD
Role: STUDY_CHAIR
St Olavs Hospital - Trondheim University Hospital and PRC, European Palliative Care Research Center
Jon H Loge, MD, Prof.
Role: STUDY_CHAIR
National Resource Centre for Studies of Late Effects after Cancer Treatment, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Department of Behavioral Sciences in Medicine, University of Oslo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Olavs Hospital
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Berger O, Gronberg BH, Loge JH, Kaasa S, Sand K. Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study. BMC Cancer. 2018 Apr 3;18(1):381. doi: 10.1186/s12885-018-4164-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REK2012/1238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.